PRIA Logo™
S4066119th CongressWALLET

Safeguarding Women from Chemical Abortion Act

Sponsored By: Senator Hawley, Josh [R-MO]

Introduced

Summary

Withdraw federal approval for mifepristone used to terminate intrauterine pregnancy. The bill would also create a federal private right of action so people harmed by that drug can sue manufacturers.

Show full summary
  • Women and families: Would limit the legal use and interstate availability of mifepristone for termination of intrauterine pregnancy by deeming those approvals withdrawn 14 days after enactment and treating introduction into interstate commerce as unlawful.
  • Manufacturers: Would expose makers of the approved mifepristone to federal liability for bodily injury or mental harm linked to the drug and allow suits for compensatory and punitive damages and attorney fees in federal or state court, with the remedy effective 90 days after enactment.
  • Labeling and market rules: Would deem mifepristone misbranded if labeling says it may be used for termination of intrauterine pregnancy or with another drug for that purpose, and would bar interstate commerce of products whose approval has been withdrawn.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

2 provisions identified: 1 benefits, 1 costs, 0 mixed.

Remove federal approval for mifepristone

If enacted, this bill would treat FDA approvals for mifepristone (Mifeprex, RU-486) for ending intrauterine pregnancy as withdrawn 14 days after enactment. It would also treat selling or shipping such withdrawn products across state lines as a violation of the Federal Food, Drug, and Cosmetic Act. Labels saying the drug can be used to end pregnancy or with another drug for that purpose would be deemed misbranded. If enacted, patients could lose nearby access to the drug, face travel or higher out-of-pocket costs, or need other procedures.

New right to sue mifepristone makers

If enacted, this bill would create a federal private right of action for individuals who suffer bodily injury or mental-health harm tied to use of mifepristone approved for ending intrauterine pregnancy. A person harmed could sue the manufacturer in federal or state court for compensatory and punitive damages, and recover attorney fees and costs. This new cause of action would take effect 90 days after enactment.

Sponsors & CoSponsors

Sponsor

Hawley, Josh [R-MO]

MO • R

Cosponsors

  • Sen. Cornyn, John [R-TX]

    TX • R

    Sponsored 3/12/2026

  • Sen. Blackburn, Marsha [R-TN]

    TN • R

    Sponsored 3/18/2026

  • Sen. Budd, Ted [R-NC]

    NC • R

    Sponsored 3/23/2026

  • Sen. Tuberville, Tommy [R-AL]

    AL • R

    Sponsored 3/25/2026

  • Sen. Moreno, Bernie [R-OH]

    OH • R

    Sponsored 4/15/2026

  • Sen. Lankford, James [R-OK]

    OK • R

    Sponsored 4/20/2026

  • Sen. Rounds, Mike [R-SD]

    SD • R

    Sponsored 6/23/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation